Antiretroviral drug concentrations in lymph nodes: A cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans

Erin Burgunder, John K. Fallon, Nicole White, Amanda P. Schauer, Craig Sykes, Leila Remling-Mulder, Martina Kovarova, Lourdes Adamson, Paul A Luciw, J. Victor Garcia, Ramesh Akkina, Philip C. Smith, Angela D.M. Kashuba

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a “kick and kill” strategy for human immunodeficiency virus (HIV) eradication, protective concentrations of antiretrovirals (ARVs) in the lymph node are important to prevent vulnerable cells from further HIV infection. However, the factors responsible for drug distribution and concentration into these tissues are largely unknown. Although humanized mice and nonhuman primates (NHPs) are crucial to HIV research, ARV tissue pharmacology has not been well characterized across species. This study investigated the influence of drug transporter expression, viral infection, and sex on ARV penetration within lymph nodes of animal models and humans. Six ARVs were dosed for 10 days in humanized mice and NHPs. Plasma and lymph nodes were collected at necropsy, 24 hours after the last dose. Human lymph node tissue and plasma from deceased patients were collected from tissue banks. ARV, active metabolite, and endogenous nucleotide concentrations were measured by liquid chromatography-tandem mass spectrometry, and drug transporter expression was measured using quantitative polymerase chain reaction and quantitative targeted absolute proteomics. In NHPs and humans, lymph node ARV concentrations were greater than or equal to plasma, and tenofovir diphosphate/ deoxyadenosine triphosphate concentration ratios achieved efficacy targets in lymph nodes from all three species. There was no effect of infection or sex on ARV concentrations. Low drug transporter expression existed in lymph nodes from all species, and no predictive relationships were found between transporter gene/protein expression and ARV penetration. Overall, common preclinical models of HIV infection were well suited to predict human ARV exposure in lymph nodes, and low transporter expression suggests primarily passive drug distribution in these tissues.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume370
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Virus Diseases
Primates
Lymph Nodes
Pharmaceutical Preparations
HIV
Tissue Banks
Tissue Distribution
Tandem Mass Spectrometry
Liquid Chromatography
Proteomics
Nucleotides
Animal Models
Pharmacology
Gene Expression
Polymerase Chain Reaction
Infection
Research

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Antiretroviral drug concentrations in lymph nodes : A cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans. / Burgunder, Erin; Fallon, John K.; White, Nicole; Schauer, Amanda P.; Sykes, Craig; Remling-Mulder, Leila; Kovarova, Martina; Adamson, Lourdes; Luciw, Paul A; Victor Garcia, J.; Akkina, Ramesh; Smith, Philip C.; Kashuba, Angela D.M.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 370, No. 3, 01.01.2019, p. 360-368.

Research output: Contribution to journalArticle

Burgunder, Erin ; Fallon, John K. ; White, Nicole ; Schauer, Amanda P. ; Sykes, Craig ; Remling-Mulder, Leila ; Kovarova, Martina ; Adamson, Lourdes ; Luciw, Paul A ; Victor Garcia, J. ; Akkina, Ramesh ; Smith, Philip C. ; Kashuba, Angela D.M. / Antiretroviral drug concentrations in lymph nodes : A cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans. In: Journal of Pharmacology and Experimental Therapeutics. 2019 ; Vol. 370, No. 3. pp. 360-368.
@article{caf23142821e4241a0b17dc129a7c6fe,
title = "Antiretroviral drug concentrations in lymph nodes: A cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans",
abstract = "In a “kick and kill” strategy for human immunodeficiency virus (HIV) eradication, protective concentrations of antiretrovirals (ARVs) in the lymph node are important to prevent vulnerable cells from further HIV infection. However, the factors responsible for drug distribution and concentration into these tissues are largely unknown. Although humanized mice and nonhuman primates (NHPs) are crucial to HIV research, ARV tissue pharmacology has not been well characterized across species. This study investigated the influence of drug transporter expression, viral infection, and sex on ARV penetration within lymph nodes of animal models and humans. Six ARVs were dosed for 10 days in humanized mice and NHPs. Plasma and lymph nodes were collected at necropsy, 24 hours after the last dose. Human lymph node tissue and plasma from deceased patients were collected from tissue banks. ARV, active metabolite, and endogenous nucleotide concentrations were measured by liquid chromatography-tandem mass spectrometry, and drug transporter expression was measured using quantitative polymerase chain reaction and quantitative targeted absolute proteomics. In NHPs and humans, lymph node ARV concentrations were greater than or equal to plasma, and tenofovir diphosphate/ deoxyadenosine triphosphate concentration ratios achieved efficacy targets in lymph nodes from all three species. There was no effect of infection or sex on ARV concentrations. Low drug transporter expression existed in lymph nodes from all species, and no predictive relationships were found between transporter gene/protein expression and ARV penetration. Overall, common preclinical models of HIV infection were well suited to predict human ARV exposure in lymph nodes, and low transporter expression suggests primarily passive drug distribution in these tissues.",
author = "Erin Burgunder and Fallon, {John K.} and Nicole White and Schauer, {Amanda P.} and Craig Sykes and Leila Remling-Mulder and Martina Kovarova and Lourdes Adamson and Luciw, {Paul A} and {Victor Garcia}, J. and Ramesh Akkina and Smith, {Philip C.} and Kashuba, {Angela D.M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1124/jpet.119.259150",
language = "English (US)",
volume = "370",
pages = "360--368",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Antiretroviral drug concentrations in lymph nodes

T2 - A cross-species comparison of the effect of drug transporter expression, viral infection, and sex in humanized mice, nonhuman primates, and humans

AU - Burgunder, Erin

AU - Fallon, John K.

AU - White, Nicole

AU - Schauer, Amanda P.

AU - Sykes, Craig

AU - Remling-Mulder, Leila

AU - Kovarova, Martina

AU - Adamson, Lourdes

AU - Luciw, Paul A

AU - Victor Garcia, J.

AU - Akkina, Ramesh

AU - Smith, Philip C.

AU - Kashuba, Angela D.M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In a “kick and kill” strategy for human immunodeficiency virus (HIV) eradication, protective concentrations of antiretrovirals (ARVs) in the lymph node are important to prevent vulnerable cells from further HIV infection. However, the factors responsible for drug distribution and concentration into these tissues are largely unknown. Although humanized mice and nonhuman primates (NHPs) are crucial to HIV research, ARV tissue pharmacology has not been well characterized across species. This study investigated the influence of drug transporter expression, viral infection, and sex on ARV penetration within lymph nodes of animal models and humans. Six ARVs were dosed for 10 days in humanized mice and NHPs. Plasma and lymph nodes were collected at necropsy, 24 hours after the last dose. Human lymph node tissue and plasma from deceased patients were collected from tissue banks. ARV, active metabolite, and endogenous nucleotide concentrations were measured by liquid chromatography-tandem mass spectrometry, and drug transporter expression was measured using quantitative polymerase chain reaction and quantitative targeted absolute proteomics. In NHPs and humans, lymph node ARV concentrations were greater than or equal to plasma, and tenofovir diphosphate/ deoxyadenosine triphosphate concentration ratios achieved efficacy targets in lymph nodes from all three species. There was no effect of infection or sex on ARV concentrations. Low drug transporter expression existed in lymph nodes from all species, and no predictive relationships were found between transporter gene/protein expression and ARV penetration. Overall, common preclinical models of HIV infection were well suited to predict human ARV exposure in lymph nodes, and low transporter expression suggests primarily passive drug distribution in these tissues.

AB - In a “kick and kill” strategy for human immunodeficiency virus (HIV) eradication, protective concentrations of antiretrovirals (ARVs) in the lymph node are important to prevent vulnerable cells from further HIV infection. However, the factors responsible for drug distribution and concentration into these tissues are largely unknown. Although humanized mice and nonhuman primates (NHPs) are crucial to HIV research, ARV tissue pharmacology has not been well characterized across species. This study investigated the influence of drug transporter expression, viral infection, and sex on ARV penetration within lymph nodes of animal models and humans. Six ARVs were dosed for 10 days in humanized mice and NHPs. Plasma and lymph nodes were collected at necropsy, 24 hours after the last dose. Human lymph node tissue and plasma from deceased patients were collected from tissue banks. ARV, active metabolite, and endogenous nucleotide concentrations were measured by liquid chromatography-tandem mass spectrometry, and drug transporter expression was measured using quantitative polymerase chain reaction and quantitative targeted absolute proteomics. In NHPs and humans, lymph node ARV concentrations were greater than or equal to plasma, and tenofovir diphosphate/ deoxyadenosine triphosphate concentration ratios achieved efficacy targets in lymph nodes from all three species. There was no effect of infection or sex on ARV concentrations. Low drug transporter expression existed in lymph nodes from all species, and no predictive relationships were found between transporter gene/protein expression and ARV penetration. Overall, common preclinical models of HIV infection were well suited to predict human ARV exposure in lymph nodes, and low transporter expression suggests primarily passive drug distribution in these tissues.

UR - http://www.scopus.com/inward/record.url?scp=85071354671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071354671&partnerID=8YFLogxK

U2 - 10.1124/jpet.119.259150

DO - 10.1124/jpet.119.259150

M3 - Article

C2 - 31235531

AN - SCOPUS:85071354671

VL - 370

SP - 360

EP - 368

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -